Digestive Health Clinical Studies

  • Improved large intestinal health – Numerous biomarkers are generally accepted in measuring the general health and function of the large intestine. These include production of short-chain fatty acids, reduced pH, reduced concentrations of ammonia and phenol, decreased bile acids and increased fecal weight.
    • 13 clinical studies have shown positive improvements in intestinal health biomarkers.
  • Improved large intestinal function – Cessation of diarrhea caused by diseases such as rotavirus and cholera can be lifesaving.
    • 4 out of 5 clinical studies have shown reduced duration and severity of diarrhea in adults and children when resistant starch was added to their treatment.
  • Colon cancer – Numerous biomarkers are somewhat accepted in trying to develop models for prevention of colon cancer. However, large-scale clinical trials are the only accepted method of demonstrating prevention.
    • Two large cancer prevention studies demonstrated no effect of resistant starch in prevention of colon cancer in people at high risk of developing cancer. It has been hypothesized that the dose of resistant starch was insufficient and/or it was delivered too close to cancer development (i.e., it might have missed its opportunity to prevent the early stages of cancer development).
    • One of the large cancer prevention studies showed that resistant starch lowered non-colorectal cancers (particularly in the upper gastrointestinal tract including esophageal, gastric, biliary tract, pancreatic and duodenum cancers) by 60% in adults with Lynch Syndrome.  This effect was detectable in the first 10 years after a 2 year intervention and continued in the next decade. (Mathers CPR 2022)
    • Numerous clinical trials have shown improvements in cancer biomarkers. In addition, researchers are also examining pathways for cancer development within the colon for potential mechanisms of cancer prevention by resistant starch.